FDA Brief

Warning letters Drugs

FDA warning letter to

Foshan Miwei Cosmetics Co., Ltd.

High riskIssued Apr 20Posted Apr 28Center for Drug Evaluation and Research (CDER)

FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

What happened

FDA inspected the company’s drug manufacturing facility from October 20 to 24, 2025. The agency found Current Good Manufacturing Practice (CGMP) failures in release testing, component testing, stability testing, and quality unit oversight. FDA also found Trust MD SPF 30 Stem Cell Face Cream and inBlair Elevate SPF 15 Moisturizer marketed as OTC sunscreens without approved applications and with misbranded labeling.

What FDA found

  1. Your firm failed to test each batch for active ingredient strength and to test for objectionable microorganisms before release.

    21 CFR 211.165(a) and 211.165(b)
  2. Your firm failed to test each component lot for identity and other quality attributes, failed to verify supplier certificates of analysis, and failed to test high-risk components and objectionable microorganisms.

    21 CFR 211.84(d)(1), (d)(2), and (d)(6)
  3. Your firm assigned expiration dates without stability testing to support them.

    21 CFR 211.166(a)
  4. Your firm lacked a quality unit with written responsibilities and procedures for key quality operations.

    21 CFR 211.22(d)
  5. Trust MD SPF 30 Stem Cell Face Cream and inBlair Elevate SPF 15 Moisturizer are unapproved new drugs because they do not meet the OTC sunscreen monograph and have no approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  6. The same sunscreen products are misbranded because labeling is false or misleading and lacks required sunscreen directions for use.

    FD&C Act sections 502(a), 502(f)(1), and 502(ee), 21 U.S.C. 352(a), (f)(1), and (ee)

What FDA wants

FDA tells the company to correct the violations promptly and to provide detailed remediation plans, including test results for high-risk component lots no later than 30 calendar days from the letter date.

Who should pay attention

  • brands that buy OTC drugs or cosmetics from this contract manufacturer
  • importers and distributors of Trust MD or inBlair sunscreen products
  • quality teams that rely on supplier certificates of analysis for high-risk ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk